Actavis to spend $66B on Botox-maker Allergan

SHARE Actavis to spend $66B on Botox-maker Allergan

Actavis is paying $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover battle waged by Valeant Pharmaceuticals for the Botox maker.

Actavis said Monday that it will spend $219 in cash and stock for each share of Allergan.

That tops a bid for Allergan valued at about $53 billion and made last spring by Valeant Pharmaceuticals International Inc. and the hedge fund Pershing Square Capital Management. That offer totaled about $179 in cash and stock.

Allergan resisted the Valeant deal for months, but its board has unanimously approved the Actavis offer.

The Latest
Much of his art, often completed at his studio in Antioch, was inspired by trips to ancient and natural sites in the United States and Canada.
Wayne Smith shares his experience as a blind person in Chicago, and what we all could do to better accommodate people with special needs.
With no explanation, the two men abruptly refuse to take their parents’ calls.